8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $72M | -$49M | 82.1% | -59.4% | 291.8% | -86.2% | -$32M | $43M | $10M |
| 2024 | $64M | -$62M | 85.8% | -88.1% | -1374.6% | -77.6% | -$58M | $42M | $14M |
| 2023 | $50M | -$35M | 84.5% | -85.1% | -72.1% | -31.7% | -$39M | $40M | $22M |
| 2022 | $34M | -$27M | 82.4% | -79.9% | -31.5% | -27.1% | -$20M | — | $18M |
| 2021 | $29M | -$27M | 79.6% | -90.8% | -23.0% | -21.2% | -$27M | — | $111M |
| 2020 | $14M | -$42M | 79.2% | -299.2% | -58.1% | -51.0% | -$23M | — | $74M |
| 2019 | $5M | -$25M | 76.8% | -466.4% | -120.5% | -97.4% | -$20M | — | $20M |
| 2018 | $929000 | -$13M | 41.2% | -1489.9% | -90.8% | — | -$13M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $22M | -$8M | 81.9% | -31.6% | 27.5% | -16.0% | -$4M | — | $9M |
| Mar '26 | $19M | -$11M | 81.7% | -45.7% | 45.8% | -20.6% | -$10M | — | $8M |
| Dec '25 | $18M | -$12M | 81.2% | -59.1% | 69.8% | -20.6% | -$5M | $43M | $10M |
| Sep '25 | $17M | -$13M | 81.3% | -53.6% | 197.8% | -20.7% | -$6M | $42M | $15M |
| Jun '25 | $18M | -$10M | 81.2% | -60.5% | 76.9% | -17.1% | -$11M | $42M | $12M |
| Mar '25 | $19M | -$14M | 84.7% | -63.9% | 303.2% | -19.9% | -$11M | $41M | $15M |
| Dec '24 | $18M | -$12M | 87.6% | -54.1% | -257.6% | -14.5% | -$10M | $42M | $14M |
| Sep '24 | $20M | -$16M | 83.7% | -70.6% | -132.5% | -20.0% | -$11M | $43M | $19M |
| Jun '24 | $15M | -$15M | 86.1% | -102.8% | -64.4% | -17.5% | -$15M | $41M | $17M |
| Mar '24 | $11M | -$19M | 86.4% | -155.0% | -57.3% | -19.2% | -$22M | $41M | $17M |
| Dec '23 | $14M | -$7M | 87.3% | -86.5% | -14.4% | -6.3% | -$11M | $40M | $22M |
| Sep '23 | $14M | -$9M | 84.5% | -68.2% | -13.8% | -10.8% | -$9M | — | $51M |
| Jun '23 | $12M | -$10M | 81.2% | -95.0% | -15.1% | -12.0% | -$9M | — | $37M |
| Mar '23 | $11M | -$9M | 84.2% | -93.9% | -11.9% | -10.0% | -$9M | — | $28M |
| Dec '22 | $9M | -$5M | 85.8% | -62.5% | -6.3% | -5.4% | -$4M | — | $18M |
| Sep '22 | $9M | -$6M | 83.2% | -63.2% | -6.4% | -5.6% | -$3M | — | $24M |
| Jun '22 | $8M | -$6M | 83.4% | -76.3% | -6.8% | -6.1% | -$4M | — | $35M |
| Mar '22 | $8M | -$9M | 76.4% | -125.8% | -9.7% | -8.9% | -$9M | — | $24M |
| Sep '21 | $7M | -$6M | 84.5% | -84.7% | -5.3% | -4.9% | -$639000 | — | $60M |
| Jun '21 | $10M | -$5M | 80.1% | -45.7% | -4.1% | -3.8% | -$4M | — | $111M |
How the market has priced RCEL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, AVITA Medical, Inc.'s revenue has grown 38.1% per year. These are computed facts, not advice.
As of FY2025, AVITA Medical, Inc. reported $43M of total debt against $10M of cash; operating income covered interest expense -8.5×.
In FY2025, gross margin was 82.1%, operating margin -59.4%, and net margin -67.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.